MedTrace Logo

RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain

NCT01719055 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 4800

Last updated 2026-05-11

No results posted yet for this study

Summary

To compile characteristics of real-world clinical outcomes for Boston Scientific commercially approved neurostimulation systems for pain in routine clinical practice, when used according to the applicable Instructions for Use

\- and -

To evaluate the economic value and technical performance of Boston Scientific commercially approved neurostimulation systems for pain in routine clinical practice

Conditions

Interventions

DEVICE

neurostimulation system

Trial stimulation period, followed by permanent implant of a neurostimulation system for subjects with a positive trial outcome

Sponsors & Collaborators

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Natalie Bloom Lyons · Boston Scientific Corporation

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-19
Primary Completion
2035-05-31
Completion
2035-05-31

Countries

  • United States
  • Argentina
  • Australia
  • Belgium
  • Canada
  • Colombia
  • Denmark
  • Germany
  • Israel
  • Italy
  • Japan
  • Netherlands
  • Spain
  • Sweden
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01719055 on ClinicalTrials.gov